2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2454

Expression of TLR5 Strongly Correlates with Levels of TNF-a and DAS28 in RA Monocytes and Ligation of TLR5 Induces Angiogenesis in RA
Abstract Number: 698

External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients
Abstract Number: 1066

Extrathymic Autoimmune Regulator (AIRE) Expression in Rheumatoid Arthritis
Abstract Number: 1887

Facebook Support Groups in Systemic Lupus Erythematosus: Content Analysis
Abstract Number: 1815

Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Abstract Number: 1165

Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Abstract Number: 1894

Factors Associated with Confidence Level of Rheumatology Fellows in Joint Procedural Skills
Abstract Number: 2563

Factors Associated with Major Cardiovascular Events in Patients with Primary Systemic Necrotizing Vasculitides: Results of a Longitudinal Long-Term Follow-up Study
Abstract Number: 2693

Factors Associated with Person-Perceived Disability in Adults Aged 18+ with Rheumatoid Arthritis
Abstract Number: 1899

Factors Contributing to Non-Publication of Abstracts Presented At the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting
Abstract Number: 456

Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
Abstract Number: 1561

Factors Influencing Implementation of Intensive Treatment Strategies for Early Rheumatoid Arthritis
Abstract Number: 1088

Factors Influencing Long-Term Recovery of Total Knee Arthroplasty
Abstract Number: 78

Factors Influencing On the Discordance Between 2011 ACR/EULAR Criteria and Physician’s Clinical Judgment for Remission in Rheumatoid Arthritis Patients
Abstract Number: 1827

Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].